Which has preferable valuation & earnings, GNCAQ or VRPX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A

Is GNCAQ or VRPX more profitable?

Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34% -338.29%

Which has stronger earnings and valuation, NAVB or GNCAQ?

Genocea Biosciences has lower revenue, but higher earnings than Navidea Biopharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is NAVB or GNCAQ more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Genocea Biosciences N/A N/A N/A

Which has higher valuation and earnings, GNCAQ or GNCA?

Genocea Biosciences has higher earnings, but lower revenue than Genocea Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is GNCAQ or GNCA more profitable?

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Which has stronger earnings & valuation, PXMD or GNCAQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is PXMD or GNCAQ more profitable?

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Genocea Biosciences N/A N/A N/A

Which has higher valuation & earnings, ARDS or GNCAQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is ARDS or GNCAQ more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Genocea Biosciences N/A N/A N/A

Genocea Biosciences (GNCAQ) Competitors

Compare

GNCAQ vs. VRPX, NAVB, GNCA, PXMD, and ARDS

Should you buy Genocea Biosciences stock or one of its competitors? MarketBeat compares Genocea Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genocea Biosciences include Virpax Pharmaceuticals (VRPX), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, indicating that its stock price is 1,752% less volatile than the broader market.

Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Virpax Pharmaceuticals	Neutral

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Genocea Biosciences and Virpax Pharmaceuticals tied by winning 3 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Genocea Biosciences	Neutral

Genocea Biosciences has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Genocea Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Genocea Biosciences	Neutral

Genocea Biosciences has higher earnings, but lower revenue than Genocea Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

Summary

Genocea Biosciences beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Genocea Biosciences	Neutral

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Genocea Biosciences	N/A	N/A	N/A

Summary

Genocea Biosciences beats PaxMedica on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Genocea Biosciences	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

Aridis Pharmaceuticals has a beta of 44.97, indicating that its stock price is 4,397% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 4 of the 4 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

GNCAQ vs. The Competition

Export

Metric	Genocea Biosciences	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5K	$353.08M	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	0.00	N/A	28.02	24.70
Price / Sales	N/A	228.84	540.37	99.46
Price / Cash	N/A	22.44	49.26	57.09
Price / Book	N/A	4.86	10.96	6.46
Net Income	N/A	-$141.03M	$3.57B	$337.01M

Genocea Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	$5K	N/A	N/A	70
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-97.1%	$14K	N/A	N/A	7
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genocea Biosciences (GNCAQ) Competitors

GNCAQ vs. VRPX, NAVB, GNCA, PXMD, and ARDS

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Summary

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Summary

How does Genocea Biosciences compare to Genocea Biosciences?

Summary

How does Genocea Biosciences compare to PaxMedica?

Summary

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

GNCAQ vs. The Competition

Genocea Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genocea Biosciences (GNCAQ) Competitors

GNCAQ vs. VRPX, NAVB, GNCA, PXMD, and ARDS

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Which has preferable valuation & earnings, GNCAQ or VRPX?

Which has more volatility and risk, GNCAQ or VRPX?

Is GNCAQ or VRPX more profitable?

Does the media prefer GNCAQ or VRPX?

Do insiders & institutionals believe in GNCAQ or VRPX?

Summary

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Does the media refer more to NAVB or GNCAQ?

Which has stronger earnings and valuation, NAVB or GNCAQ?

Which has more risk & volatility, NAVB or GNCAQ?

Do insiders & institutionals believe in NAVB or GNCAQ?

Is NAVB or GNCAQ more profitable?

Summary

How does Genocea Biosciences compare to Genocea Biosciences?

Which has more volatility & risk, GNCAQ or GNCA?

Do insiders & institutionals believe in GNCAQ or GNCA?

Is GNCAQ or GNCA more profitable?

Does the media favor GNCAQ or GNCA?

Which has higher valuation and earnings, GNCAQ or GNCA?

Summary

How does Genocea Biosciences compare to PaxMedica?

Which has stronger earnings & valuation, PXMD or GNCAQ?

Do institutionals and insiders hold more shares of PXMD or GNCAQ?

Which has more volatility and risk, PXMD or GNCAQ?

Does the media prefer PXMD or GNCAQ?

Is PXMD or GNCAQ more profitable?

Summary

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Which has higher valuation & earnings, ARDS or GNCAQ?

Do institutionals and insiders hold more shares of ARDS or GNCAQ?

Does the media favor ARDS or GNCAQ?

Is ARDS or GNCAQ more profitable?

Which has more risk & volatility, ARDS or GNCAQ?

Summary

New MarketBeat Followers Over Time

GNCAQ vs. The Competition

Genocea Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools